US 8546331
Modulation of pathogenic CD14+/CD16+ monocytes
granted A61KA61K2039/505A61P
Quick answer
US patent 8546331 (Modulation of pathogenic CD14+/CD16+ monocytes) held by XBIOTECH INC. expires Mon Sep 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- XBIOTECH INC.
- Grant date
- Tue Oct 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61P, A61P1/04, A61P19/02